SPAF Programs
Interactive Medical Intelligence
The most comprehensive multimedia CME resource for SPAF. The “Best and the Brightest” address the trickiest and toughest questions, issues and clinical dilemmas in stroke prevention in Atrial Fibrillation.
Webcast
Program Chair Samuel Z. Goldhaber, MD, of Harvard Medical School, is joined by a Christian Ruff, also of Harvard Medical School, Jonathan Halperin, MD, of Mount Sinai School of Medicine, and Alexander Turpie, MD, of McMaster University in a national congress satellite symposium on new and established therapies for stroke prevention in atrial fibrillation SPAF.
Webcast
Program Chair Samuel Z. Goldhaber, MD, of Harvard Medical School, is joined by a Deepak Bhatt, MD, also of Harvard Medical School, and Jonathan Halperin, MD, of Mount Sinai School of Medicine, in a comprehensive review of and established therapies for stroke prevention in atrial fibrillation SPAF.
Webcast
Program Chair Samuel Z. Goldhaber of Harvard Medical School is joined by a distinguished panel of experts in a review of late-breaking trials for new and established therapies for stroke prevention in atrial fibrillation (SPAF). Dr. Goldhaber uses risk stratification to navigate the complex maze of SPAF.
Webcast
Gerald V. Naccarelli, M.D., the Bernard Trabin Chair in Cardiology, Professor of Medicine, and Chief, Division of Cardiology at Penn State Heart and Vascular Institute, reviews principles, evidence, and guidelines focusing on rhythm control and optimizing outcome domains in patients with atrial fibrillation.
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads a panel of international experts in the iQ&A Interactive Medical Intelligence Zone for Stroke Prevention in Atrial Fibrillation. Dr. Goldhaber and this forum of experts address the most pressing questions on the rapidly evolving, multidimensional landscape of risk-specific interventions for stroke prevention in the setting of atrial fibrillation.
Peter Libby, MD, FACC, Chief of Cardiovascular Medicine at Brigham and Women’s Hospital, chairs an expert faculty as they study the latest developments and landscape changes in atrial fibrillation, focusing on emerging strategies for stroke prevention.
The New Frontiers in Atrial Fibrillation
There has been growing interest in identifying oral anticoagulants that can achieve safe and effective prophylaxis for stroke prevention, with minimal risk of bleeding and without the need for monitoring of clotting parameters. Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an expert faculty in discussing the latest strategies for stroke prevention in the setting of atrial fibrillation, reviews the latest American College of Chest Physicians and ACC/AHA Guidelines for stroke prevention, and analyzes recent landmark clinical trials in anticoagulation.
